{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:22:14Z","timestamp":1779175334560,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"1.3.5 Project for Artificial Intelligence","award":["No. ZYAI24039"],"award-info":[{"award-number":["No. ZYAI24039"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82370192, U24A20680"],"award-info":[{"award-number":["No. 82370192, U24A20680"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06565-x","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:01:00Z","timestamp":1755752460000},"page":"4837-4841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-plasma cell therapy in patients with monoclonal gammopathy-associated refractory pure red cell aplasia: A report of three cases and literature review"],"prefix":"10.1007","volume":"104","author":[{"given":"Li","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"21","key":"6565_CR1","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","volume":"128","author":"RT Means Jr","year":"2016","unstructured":"Means RT Jr (2016) Pure red cell aplasia. Blood 128(21):2504\u20132509. https:\/\/doi.org\/10.1182\/blood-2016-05-717140","journal-title":"Blood"},{"issue":"6","key":"6565_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/bjh.14012","volume":"173","author":"N Korde","year":"2016","unstructured":"Korde N, Zhang Y, Loeliger K, Poon A, Simakova O, Zingone A et al (2016) Monoclonal gammopathy-associated pure red cell aplasia. Br J Haematol 173(6):876\u2013883. https:\/\/doi.org\/10.1111\/bjh.14012","journal-title":"Br J Haematol"},{"issue":"1","key":"6565_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3324\/haematol.11655","volume":"93","author":"M Hirokawa","year":"2008","unstructured":"Hirokawa M, Sawada K, Fujishima N, Nakao S, Urabe A, Dan K et al (2008) Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 93(1):27\u201333","journal-title":"Haematologica"},{"issue":"15","key":"6565_CR4","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1182\/blood.2021010898","volume":"137","author":"C Gurnari","year":"2021","unstructured":"Gurnari C, Maciejewski JP (2021) How i manage acquired pure red cell aplasia in adults. Blood 137(15):2001\u20132009. https:\/\/doi.org\/10.1182\/blood.2021010898","journal-title":"Blood"},{"issue":"4","key":"6565_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","volume":"142","author":"K Sawada","year":"2008","unstructured":"Sawada K, Fujishima N, Hirokawa M (2008) Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 142(4):505\u2013514. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07216.x","journal-title":"Br J Haematol"},{"key":"6565_CR6","doi-asserted-by":"publisher","unstructured":"Sarathy KS, Ramakrishna R, Baig WW, Manoharan A (2014) Acquired pure red cell aplasia in patients with plasma cell neoplasm and long term remission with bortezomib therapy. J Hematol Malignancies 3(2). https:\/\/doi.org\/10.5430\/jhm.v3n2p37","DOI":"10.5430\/jhm.v3n2p37"},{"key":"6565_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lrr.2018.06.005","volume":"10","author":"T Ito","year":"2018","unstructured":"Ito T, Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y et al (2018) Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide. Leuk Res Rep 10:4\u20136. https:\/\/doi.org\/10.1016\/j.lrr.2018.06.005","journal-title":"Leuk Res Rep"},{"key":"6565_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2021.102573","volume":"89","author":"L Zhang","year":"2021","unstructured":"Zhang L, Chen N, Xu Z, Liang Q, Pan H, Zhao J et al (2021) Good treatment-free survival of monoclonal gammopathy of undetermined significance associated pure red cell aplasia after bortezomib plus dexamethasone. Blood Cells Mol Dis 89:102573. https:\/\/doi.org\/10.1016\/j.bcmd.2021.102573","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"6565_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/jha2.964","volume":"5","author":"CS Michel","year":"2024","unstructured":"Michel CS, Fehr EM, Nolte H, Beck J, Kreft A, Rauschkolb-Olk KT et al (2024) Effective treatment of refractory monoclonal gammopathy\u2010associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone. EJHaem 5(4):838\u2013841. https:\/\/doi.org\/10.1002\/jha2.964","journal-title":"EJHaem"},{"issue":"10","key":"6565_CR10","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3324\/haematol.2022.281398","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Bleeker J, Lynch D, Olteanu H, Letendre L, Tefferi A (2022) Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. Haematologica 107(10):2523\u20132526. https:\/\/doi.org\/10.3324\/haematol.2022.281398","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06565-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06565-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06565-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:48Z","timestamp":1761283848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06565-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6565"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06565-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the West China Hospital of Sichuan University Ethics Committee [Approval Number: Approval in 2023, No. (413)]. Informed consent was obtained from the patients for the publication of any potentially identifiable data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}